Anzeige
Mehr »
Mittwoch, 22.10.2025 - Börsentäglich über 12.000 News
Uran-Aktien gehen durch die Decke - diese Aktie könnte der nächste Highflyer sein!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JKVH | ISIN: IE00B56GVS15 | Ticker-Symbol: 8AK
Tradegate
21.10.25 | 21:37
27,200 Euro
0,00 % 0,000
1-Jahres-Chart
ALKERMES PLC Chart 1 Jahr
5-Tage-Chart
ALKERMES PLC 5-Tage-Chart
RealtimeGeldBriefZeit
26,80027,40021.10.
26,60027,60021.10.

Aktuelle News zur ALKERMES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoAlkermes plc: Alkermes to Report Third Quarter Financial Results on October 28, 2025226DUBLIN, Oct. 20, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Thursday, Oct. 23, 2025 to...
► Artikel lesen
MoAlkermes: UBS hebt Kursziel nach Studiendaten auf 46 US-Dollar an4
ALKERMES Aktie jetzt für 0€ handeln
06.10.Piper Sandler reiterates Overweight rating on Alkermes stock ahead of trial2
26.09.Alkermes upgraded at RBC Capital Markets ahead of key catalyst3
26.09.9 Analysts Assess Alkermes: What You Need To Know2
26.09.Alkermes stock rating upgraded by RBC Capital on narcolepsy drug potential2
12.09.Alkermes Names Joshua Reed Chief Financial Officer3
12.09.Alkermes Appoints Joshua Reed As CFO1
12.09.Alkermes appoints Joshua Reed as new CFO effective Monday1
12.09.Alkermes appoints new CFO2
12.09.Alkermes plc: Alkermes Appoints Joshua Reed as Chief Financial Officer281DUBLIN, Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025....
► Artikel lesen
11.09.Alkermes plc: Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards Program276- Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project - - Areas of Interest Expanded to Include Sleep and Circadian Disturbances Associated With Bipolar...
► Artikel lesen
09.09.Takeda Is Waking Up the Narcolepsy Market With First-in-Class Drug, But Alkermes Is on Its Heels7
08.09.Alkermes plc. - 8-K, Current Report -
08.09.Alkermes stock maintains Buy rating at Stifel following sleep disorder data1
08.09.Takeda, Alkermes lift lid on data for rival narcolepsy hopefuls as race to market heats up11
08.09.Alkermes reports positive phase 2 results for narcolepsy drug3
08.09.Alkermes plc: Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025358- First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily Dosing Across a Range of...
► Artikel lesen
03.09.Deep Dive Into Alkermes Stock: Analyst Perspectives (7 Ratings)1
25.08.Alkermes plc: Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025258- Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease...
► Artikel lesen
Weiter >>
94 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1